Status:
UNKNOWN
Ablation of Consecutive Atrial Tachycardia
Lead Sponsor:
Evangelical Hospital Düsseldorf
Conditions:
Heart Arrhythmia
Heart Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of pa...
Eligibility Criteria
Inclusion
- Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery
- Surface ECG-documentation of AT as primary clinical arrhythmia
- ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms
Exclusion
- \< 18 years
- No previous atrial fibrillation ablation procedure or cardiac surgery
- Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment
- History of hemorrhagic diathesis or other coagulopathies
- Contraindications for oral anticoagulation
- Hyper- or hypothyroidism
- Has any condition that would make participation not be in the best interest of the subject
Key Trial Info
Start Date :
December 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05239364
Start Date
December 22 2020
End Date
December 1 2024
Last Update
November 10 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Evangelic Hospital Düsseldorf
Düsseldorf, North Rhine-Westfalia, Germany, 40217
2
Evangelic Hospital Hagen-Haspe
Hagen, Germany
3
Asklepios St. Georg
Hamburg, Germany
4
Universitätsklinikum Schleswig Holstein
Kiel, Germany